Guggenheim Initiates Coverage On Twist Bioscience with Buy Rating, Announces Price Target of $53
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has initiated coverage on Twist Bioscience (NASDAQ:TWST) with a Buy rating and set a price target of $53.
June 05, 2024 | 10:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim has initiated coverage on Twist Bioscience with a Buy rating and set a price target of $53, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $53 by a reputable analyst from Guggenheim is likely to boost investor confidence and drive short-term price appreciation for Twist Bioscience.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100